Noel Dybdal - Director and Principal Scientist, Safety Assessment Pathology, Department of Development Sciences

Noel Dybdal

Director and Principal Scientist, Safety Assessment Pathology, Department of Development Sciences

"The environment at Genentech is always stimulating and the opportunity to work with some of the brightest and most innovative scientists imaginable working toward a common and urgent goal of providing new and better options for patients is continuously rewarding. The urgency of our mission drives us to bring our best selves to work every day."
25
Years at Genentech
29
Publications
1
Awards & Honors

Following completion of residency training in Pathology and post-doctoral work in Endocrine Pathology, I joined Genentech as a Scientist-Pathologist in 1992. I was most attracted by the Genentech reputation for rigor. Happily, given my interest and training in pathology, receptor ligand biology and radioimmunoassay and immunohistochemistry techniques, I became involved early with the oncology program teams, in particular the anti-HER2 projects. My responsibilities have also included growing the Safety Assessment Pathology group to meet the needs of all Genentech programs.

Featured Publication

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.

Breast Cancer Res Treat. 2005 Sep; 93(1): 3-11.

Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF.